Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 3;13(1):44.
doi: 10.1186/s40035-024-00439-4.

A novel plasma p-tau181 assay as a specific biomarker of tau pathology in Alzheimer's disease

Affiliations

A novel plasma p-tau181 assay as a specific biomarker of tau pathology in Alzheimer's disease

Kenji Tagai et al. Transl Neurodegener. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Hitoshi Shimada, Ming-Rong Zhang, and Makoto Higuchi hold patents on compounds related to the present report (JP 5422782/EP 12 884 742.3/CA2894994/HK1208672).

Figures

Fig. 1
Fig. 1
Correlations of plasma mid-p-tau or N-p-tau level with tau or amyloid PET in the subjects with AD continuum. a The correlation between plasma mid-p-tau181 level and 18F-florzorotau tau PET is depicted through its topographical representation (P < 0.05, FWE-corrected). b, c Scatter plots of the correlation between plasma mid-p-tau181 level and tau PET tracer accumulation in each ROI. Pearson's correlation analysis was employed to calculate the r and P values. Statistical significance was established at P < 0.0125, corrected for multiple comparisons using the Bonferroni method. Regression analysis, indicated by a straight or curved line, depicts the preferred model, with its goodness of fit quantified using the R2 value. d Topographical representation of the correlation between plasma N-p-tau181 level and tau PET (P < 0.05, uncorrected). e, f Scatter plots of the correlation between plasma N-p-tau181 level and tau PET tracer accumulation in each ROI. The procedure for the correlation analysis was the same as that in b and c. g Topographical representation of the correlations of each plasma p-tau181 assay with amyloid- (left column) and tau- (right column) PET in the CN and AD continuum cohort (P < 0.05, FWE-corrected). h Bar graphs illustrating beta coefficient values of amyloid and tau PET in multiple liner regression analysis with each p-tau assay. *P < 0.05, **P < 0.005, ****P < 0.0005. P-values were corrected for multiple comparisons using Bonferonni correction with the number of explanatory variables

References

    1. Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324:772–81. 10.1001/jama.2020.12134 - DOI - PMC - PubMed
    1. Karikari TK, Ashton NJ, Brinkmalm G, Brum WS, Benedet AL, Montoliu-Gaya L, et al. Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nat Rev Neurol. 2022;18:400–18. 10.1038/s41582-022-00665-2 - DOI - PubMed
    1. Palmqvist S, Tideman P, Cullen N, Zetterberg H, Blennow K. Alzheimer’s Disease Neuroimaging Initiative, et al. Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med. 2021;27:1034–42. 10.1038/s41591-021-01348-z - DOI - PubMed
    1. Therriault J, Vermeiren M, Servaes S, Tissot C, Ashton NJ, Benedet AL, et al. Association of phosphorylated tau biomarkers with amyloid positron emission tomography vs tau positron emission tomography. JAMA Neurol. 2023;80(2):188–99. 10.1001/jamaneurol.2022.4485 - DOI - PMC - PubMed
    1. Ossenkoppele R, Rabinovici GD, Smith R, Cho H, Schöll M, Strandberg O, et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2018;320:1151–62. 10.1001/jama.2018.12917 - DOI - PMC - PubMed

Publication types

LinkOut - more resources